Andres Maldonado
Stock Analyst at HC Wainwright & Co.
(3.69)
# 799
Out of 4,996 analysts
86
Total ratings
48.24%
Success rate
8.98%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Andres Maldonado
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| IMAB I-Mab | Reiterates: Buy | $7 | $3.48 | +101.15% | 1 | Jul 9, 2025 | |
| IBRX ImmunityBio | Reiterates: Buy | $8 | $2.54 | +214.96% | 4 | Jun 4, 2025 | |
| AURA Aura Biosciences | Assumes: Buy | $22 | $6.16 | +257.14% | 1 | May 28, 2025 | |
| ZNTL Zentalis Pharmaceuticals | Reiterates: Buy | $10 | $1.55 | +545.16% | 1 | May 15, 2025 | |
| CRBP Corbus Pharmaceuticals Holdings | Maintains: Buy | $50 → $40 | $12.11 | +230.31% | 2 | May 7, 2025 | |
| TCRX TScan Therapeutics | Maintains: Buy | $15 → $10 | $1.85 | +440.54% | 1 | May 7, 2025 | |
| ERAS Erasca | Reiterates: Buy | $6 | $2.08 | +188.46% | 10 | Apr 30, 2025 | |
| FHTX Foghorn Therapeutics | Reiterates: Buy | $13 | $4.86 | +167.49% | 1 | Apr 30, 2025 | |
| STRO Sutro Biopharma | Reiterates: Neutral | $2 | $0.89 | +125.58% | 1 | Apr 29, 2025 | |
| TARA Protara Therapeutics | Reiterates: Buy | $23 | $4.25 | +441.18% | 1 | Apr 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $75 | $37.54 | +99.79% | 13 | Apr 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $36 | $6.77 | +431.76% | 14 | Apr 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $18 → $6 | $2.09 | +187.08% | 5 | Mar 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $15 | $2.07 | +624.64% | 16 | Mar 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $25 | $6.49 | +285.21% | 2 | Mar 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $40 → $50 | $38.75 | +29.03% | 13 | Nov 26, 2024 |
I-Mab
Jul 9, 2025
Reiterates: Buy
Price Target: $7
Current: $3.48
Upside: +101.15%
ImmunityBio
Jun 4, 2025
Reiterates: Buy
Price Target: $8
Current: $2.54
Upside: +214.96%
Aura Biosciences
May 28, 2025
Assumes: Buy
Price Target: $22
Current: $6.16
Upside: +257.14%
Zentalis Pharmaceuticals
May 15, 2025
Reiterates: Buy
Price Target: $10
Current: $1.55
Upside: +545.16%
Corbus Pharmaceuticals Holdings
May 7, 2025
Maintains: Buy
Price Target: $50 → $40
Current: $12.11
Upside: +230.31%
TScan Therapeutics
May 7, 2025
Maintains: Buy
Price Target: $15 → $10
Current: $1.85
Upside: +440.54%
Erasca
Apr 30, 2025
Reiterates: Buy
Price Target: $6
Current: $2.08
Upside: +188.46%
Foghorn Therapeutics
Apr 30, 2025
Reiterates: Buy
Price Target: $13
Current: $4.86
Upside: +167.49%
Sutro Biopharma
Apr 29, 2025
Reiterates: Neutral
Price Target: $2
Current: $0.89
Upside: +125.58%
Protara Therapeutics
Apr 28, 2025
Reiterates: Buy
Price Target: $23
Current: $4.25
Upside: +441.18%
Apr 28, 2025
Reiterates: Buy
Price Target: $75
Current: $37.54
Upside: +99.79%
Apr 3, 2025
Reiterates: Buy
Price Target: $36
Current: $6.77
Upside: +431.76%
Mar 26, 2025
Maintains: Buy
Price Target: $18 → $6
Current: $2.09
Upside: +187.08%
Mar 12, 2025
Reiterates: Buy
Price Target: $15
Current: $2.07
Upside: +624.64%
Mar 11, 2025
Reiterates: Buy
Price Target: $25
Current: $6.49
Upside: +285.21%
Nov 26, 2024
Maintains: Buy
Price Target: $40 → $50
Current: $38.75
Upside: +29.03%